Myasthenia Gravis

Abstract

The basic abnormality in myasthenia gravis (MG) is a reduction in acetylcholine receptors (AChRs) at neuromuscular junctions due to the effects of autoantibodies that are directed against the AChRs in most patients, or against neighboring proteins involved in the clustering of AChRs (MuSK, LRP-4, or agrin). Clinically, MG is characterized by muscle weakness and fatigue, often in typical patterns. The diagnosis may be missed early, and depends on the recognition of clinical manifestations, the measurement of autoantibodies, and/or electrophysiological features. The treatment of MG involves the enhancement of neuromuscular transmission by anticholinesterase drugs (pyridostigmine), and by immunotherapy. Therapy should be designed to improve the clinical features quickly, and keep the symptoms in abeyance over the long term. Rapid improvement can be achieved when necessary by the administration of intravenous immunoglobulin or plasma exchange. Intermediate rates of improvement over months involve the use of adrenal corticosteroids, the calcineurin inhibitors cyclosporine or tacrolimus, and in some patients, the B-cell inhibitor rituximab. For long-term treatment, mycophenolate and azathioprine are the most effective agents. A thymectomy may also have long-term beneficial effects. The majority of MG patients can live normal lives, but most patients require lifelong treatment. The physician's skill in managing the immunotherapeutic agents and avoiding adverse side effects is of paramount importance in the treatment of MG.

Keywords

myasthenia gravis - acetylcholine receptors - autoimmunity - antibodies - immunotherapy

• References

• 1 Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330 (25) 1797-1810
• 2 Zhou L, McConville J, Chaudhry V , et al. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 2004; 30 (1) 55-60
• 3 Drachman DB, Kaminski HJ. Neuromuscular junction as Achilles' heel: yet another autoantibody?. Neurology 2014; 82 (22) 1942-1943
• 4 Bulkley GB, Bass KN, Stephenson GR , et al. Extended cervicomediastinal thymectomy in the integrated management of myasthenia gravis. Ann Surg 1997; 226 (3) 324-334 , discussion 334–335
• 5 Kearsey C, Fernando P, D'Costa D, Ferdinand P. The use of the ice pack test in myasthenia gravis. JRSM Short Rep 2010; 1 (1) 14
• 6 Beck M, Giess R, Würffel W, Magnus T, Ochs G, Toyka KV. Comparison of maximal voluntary isometric contraction and Drachman's hand-held dynamometry in evaluating patients with amyotrophic lateral sclerosis. Muscle Nerve 1999; 22 (9) 1265-1270
• 7 Hudspeth MP, Holden KR, Crawford TO. The “slurp” test: bedside evaluation of bulbar muscle fatigue. Pediatrics 2006; 118 (2) e530-e533
• 8 Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther 2004; 102 (3) 177-193
• 9 Ponseti JM, Azem J, Fort JM , et al. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis. Neurology 2005; 64 (9) 1641-1643
• 10 Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 2001; 56 (1) 94-96
• 11 Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009; 16 (2) 246-250
• 12 Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: “rebooting” with high-dose cyclophosphamide. Ann Neurol 2003; 53 (1) 29-34